What is SonoThera?
SonoThera is a privately held biotechnology enterprise dedicated to revolutionizing how genetic material is delivered into human tissues. The company's core innovation lies in its use of focused ultrasound energy to temporarily increase cell membrane permeability, allowing for the precise and repeatable delivery of therapeutic constructs without the immunogenicity or manufacturing hurdles associated with viral vectors. This platform addresses critical bottlenecks in current gene therapy, offering a more scalable and efficient approach to treating complex diseases. By eliminating the reliance on engineered viruses, SonoThera is effectively expanding the potential cargo capacity and safety profile of genetic interventions, establishing a robust market position within the competitive landscape of precision medicine.
How much funding has SonoThera raised?
SonoThera has raised a total of $185.8M across 2 funding rounds:
Series A
$60.8M
Series B
$125M
Series A (2022): $60.8M with participation from Vertex Ventures HC, Johnson & Johnson Innovation, JJDC, Illumina Ventures, and ARCH Venture Partners
Series B (2026): $125M led by Vivo Capital, Medical Excellence Capital, Vertex Ventures HC, Johnson & Johnson Innovation, ARK Investment Management, RA Capital Management, Otsuka Pharmaceutical, Bayer Canada, Alexandria, Illumina Ventures, SymBiosis, ARCH Venture Partners, CureDuchenne, Vida Ventures, and UCB
Key Investors in SonoThera
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists to commercialize innovations.
Vertex Ventures HC
A healthcare and life sciences venture capital fund that invests in biopharmaceuticals and medical devices, aiming to improve patient outcomes through innovative therapeutic approaches.
Johnson & Johnson Innovation
A strategic investment arm of a global pharmaceutical leader that partners with early-stage businesses to develop transformational healthcare solutions across multiple sectors.
What's next for SonoThera?
With the successful completion of this major enterprise-level funding round, SonoThera is poised to accelerate its clinical development programs and refine its delivery technology. The strategic backing from a diverse syndicate of healthcare-focused venture firms and pharmaceutical partners provides not only the capital required for operational scaling but also deep industry expertise to navigate the regulatory and commercialization pathways. Future efforts will likely focus on expanding the therapeutic pipeline, optimizing the ultrasound-mediated delivery system for specific tissue targets, and establishing key partnerships to validate the platform's efficacy in human clinical trials. As the company matures, its ability to demonstrate repeatable, safe, and efficient gene delivery will be the primary driver of its long-term value proposition in the global biotechnology sector.
See full SonoThera company page
